|
| Friday, March 23, 2018 |
|
|
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal |
| AbbVie GK and Eisai Co., Ltd. today announced the additional approval for a new indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, in the treatment of patients who have had an inadequate response to conventional therapy for pustular psoriasis. With this approval, HUMIRA has been approved for 10 indications in Japan. more info >> |
|
|
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A., today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA has been approved in Japan for unresectable hepatocellular carcinoma (HCC). more info >> |
|
| Wednesday, March 14, 2018 |
|
|
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary Eisai China Inc. has launched the gastrointestinal prokinetic agent Cidine in China. more info >> |
|
| Thursday, March 8, 2018 |
|
|
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A., today announced that the companies have agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai. more info >> |
|
|
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant |
| Eisai Co., Ltd. and Purdue Pharma L.P. today announced positive topline results from multiple studies of lemborexant, an investigational agent for sleep and wake regulation currently being studied for the treatment of multiple sleep disorders. more info >> |
|
| Tuesday, February 27, 2018 |
|
|
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan |
| Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. dementia diagnosis lump-sum insurance "Dementia Support" in Japan, and that Saint Plus has launched this product today. more info >> |
|
| Wednesday, February 21, 2018 |
|
|
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500) |
| Eisai Co., Ltd. announced today that it has been certified in 2018 as an Outstanding Health and Productivity Management Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry. more info >> |
|
| Friday, February 16, 2018 |
|
|
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer |
| Eisai Co., Ltd. announced today that its in-house developed anticancer agent Lenvima has been recommended by the U.K. NICE as a treatment for progressive, locally advanced or metastatic differentiated thyroid cancer in adults whose disease does not respond to radioactive iodine, in NICE's FAD. more info >> |
|
| Monday, February 12, 2018 |
|
|
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet |
| Eisai Co., Ltd. announced that the results of a Phase III study (REFLECT study, Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylatein patients with hepatocellular carcinoma (HCC) have been published in the online version of The Lancet. more info >> |
|
| Thursday, February 1, 2018 |
|
|
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan |
| Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced today that the primary endpoint was met in a Phase II/III clinical study on the investigational Parkinson's disease treatment ME2125 in patients with Parkinson's disease. more info >> |
|
|
|
